Edition:
United States

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.50USD
2:14pm EDT
Change (% chg)

$-0.02 (-0.79%)
Prev Close
$2.52
Open
$2.55
Day's High
$2.58
Day's Low
$2.48
Volume
33,571
Avg. Vol
158,591
52-wk High
$59.81
52-wk Low
$2.24

Chart for

About

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $90.58
Shares Outstanding(Mil.): 35.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Ophthotech gives update on programs for treatment of eye diseases

* Ophthotech provides update on Zimura® complement programs for treatment of eye diseases

7:18am EDT

BRIEF-Ophthotech reports second quarter 2017 financial and operating results

* Q2 earnings per share view $1.05 -- Thomson Reuters I/B/E/S

Jul 26 2017

BRIEF-Ophthotech expands focus with development for ophthalmic orphan diseases

* Ophthotech expands focus with development for ophthalmic orphan diseases

Jul 26 2017

BRIEF-Ophthotech and Novartis Pharma enters into a letter agreement with respect to licensing and commercialization agreement

* Ophthotech - on July 3, co and Novartis Pharma entered into a letter agreement with respect to licensing and commercialization agreement dated May 19, 2014

Jul 10 2017

BRIEF-David Shaw reports a 5 pct passive stake in Ophthotech Corp as of May 11, 2017

* David Shaw reports a 5.0 percent passive stake in Ophthotech Corp as of May 11, 2017 - SEC filing Source text for Eikon: Further company coverage:

May 22 2017

BRIEF-Ophthotech reports Q1 loss per share $1.20

* Ophthotech reports first quarter 2017 financial and operating results

May 03 2017

BRIEF-Ophthotech says Glenn Sblendorio to become chief executive officer

* Says David Carroll promoted to chief financial officer, effective immediately

Apr 24 2017

Competitors

Earnings vs. Estimates